Cover Image
Market Research Report
Product code 
1074663

Tumor Ablation Market-Forecast till 2030

Published: | Market Research Future | 85 Pages | Delivery time: 1-2 business days

Price

Back to Top
Tumor Ablation Market-Forecast till 2030
Published: May 10, 2022
Market Research Future
Content info: 85 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Market Overview

As per the MRFR analysis, the global tumor ablation market is estimated to witness a notable CAGR of 11.81% during the forecast period to surpass USD 2,459.74 million by the end of 2030. The major market participants in the market are proactively dealing with R&D for improving and propelling methods for tumor ablation. Moreover, there are likewise a few dangers related to the radiofrequency removal method, for example, hyperesthesia, shallow skin contaminations over the infusion site, heat harm to structures contiguous to the objective nerve, hypersensitive response to the sedative used to numb the skin, and that's only the tip of the iceberg.

The developing pervasiveness of disease is expanding the interest for compelling treatment. Unreasonable smoking and utilization of liquor and tobacco are the significant variables answerable for the rising predominance of malignant growth across the world. Expanding commonness of disease across the globe goes about as a significant driver in the worldwide tumor ablation market from 2021-to to 2030. Nonetheless, incidental effects and entanglement related to tumor ablation thwart the development of the worldwide tumor ablation market during the gauge time frame. Rising R&D exercises in tumor ablation are supposed to set out freedom in the worldwide tumor ablation market.

Market Segmentation

The market segmentation of the global tumor ablation market is carried out in terms of technology, treatment, application, and end-user.

The application segment of the global tumor ablation market is categorized into liver cancer, lung cancer, kidney cancer, and others. The treatment type divides the market based on surgical ablation, and percutaneous ablation laparoscopic ablation. Europe is the second-biggest market for growth ablation because of the development of normalized strategies and instruments for cancer ablation therapy, developing interest in medical procedure radiotherapy and chemotherapy for early recognized growths, and expanding instances of different cancer among the mid-matured and geriatric populace, and rising utilization of undesirable and cancer-causing items.

Regional Analysis

Geographically, the global tumor ablation market spans North America, Europe, Asia-Pacific, Rest of the World.

North America contributed the largest market of 40.29% in 2020 and is anticipated to lead the market during the review period. The regional market is driven by the advances in percutaneous ablation, developing interest in radiofrequency ablation for hepatocellular carcinoma, expanding geriatric populace, and development of cancer-related issues among the populace matured 65 years or more.

Europe is the second-biggest market for growth ablation because of the development of normalized strategies and instruments for cancer ablation therapy, developing interest in medical procedure radiotherapy and chemotherapy for early recognized growths, and expanding instances of different cancer among the mid-matured and geriatric populace, and rising utilization of undesirable and cancer-causing items. Asia-Pacific is supposed to fill essentially in the growth ablation market inferable from the rising utilization of cancer-causing items, for example, liquor and betel nut, restricted admission of leafy foods, a disclosure to indoor and open-air contamination, and ascend in openness to compound poisons across the region.

Key Competitors

The key players operating in the global tumor ablation include SonaCare Medical, LLC (US), Medtronic plc (Ireland), EDAP TMS (France), Angio Dynamics (US), HealthTronics, Inc (US), Johnson & Johnson (US), Boston Scientific Corporation (US), Misonix Inc (US), HistoSonics, Inc (US), Biotronik (Germany).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Product Code: MRFR/HC/5673-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 15

    • 1.1.1 MARKET SYNOPSIS 15

2 MARKET INTRODUCTION 16

  • 2.1 SCOPE OF THE STUDY 16
  • 2.2 RESEARCH OBJECTIVE 16
  • 2.3 LIST OF ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 18

  • 3.1 DATA MINING 18
  • 3.2 SECONDARY RESEARCH 19
  • 3.3 PRIMARY RESEARCH 20
    • 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 20
    • 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS 21
  • 3.4 FORECASTING TECHNIQUES 21
  • 3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
    • 3.5.1 BOTTOM-UP APPROACH 23
    • 3.5.2 TOP-DOWN APPROACH 24
  • 3.6 DATA TRIANGULATION 24
  • 3.7 VALIDATION 24

4 MARKET DYNAMICS 26

  • 4.1 OVERVIEW 26
  • 4.2 DRIVERS 27
    • 4.2.1 INCREASING PREVALENCE OF CANCER ACROSS THE GLOBE 27
    • 4.2.2 RISING DEMAND FOR MINIMALLY INVASIVE TUMOR ABLATION TECHNIQUES 27
    • 4.2.3 GROWING NUMBER OF PUBLIC-PRIVATE INITIATIVES AND FUNDING TO SUPPORT ONGOING RESEARCH ACTIVITIES RELATED TO TUMOR ABLATION 27
  • 4.3 RESTRAINTS 28
    • 4.3.1 SIDE-EFFECTS AND COMPLICATIONS ASSOCIATED WITH TUMOR ABLATION 28
    • 4.3.2 DELAY IN APPROVAL AND UNFAVORABLE REGULATORY POLICY AND REIMBURSEMENT SCENARIO 28
  • 4.4 OPPORTUNITY 29
    • 4.4.1 RISING R&D ACTIVITIES 29

5 MARKET FACTOR ANALYSIS 30

  • 5.1 VALUE CHAIN ANALYSIS 30
    • 5.1.1 R&D 31
    • 5.1.2 MANUFACTURING 31
    • 5.1.3 DISTRIBUTION & SALES 31
    • 5.1.4 POST-SALES MONITORING 31
  • 5.2 PORTER'S FIVE FORCES ANALYSIS 32
    • 5.2.1 THREAT OF NEW ENTRANTS 33
    • 5.2.2 BARGAINING POWER OF SUPPLIERS 33
    • 5.2.3 BARGAINING POWER OF BUYERS 33
    • 5.2.4 THREAT OF SUBSTITUTES 33
    • 5.2.5 INTENSITY OF RIVALRY 33
  • 5.3 COVID-19 IMPACT ANALYSIS 34
    • 5.3.1 IMPACT ON AVAILABILITY OF SURGICAL FACILITIES 34
    • 5.3.2 IMPACT ON KEY PLAYERS 34
    • 5.3.3 IMPACT ON CLINICAL TRIALS 35
    • 5.3.4 IMPACT ON SUPPLY CHAIN 35

6 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY 36

  • 6.1 OVERVIEW 36
  • 6.2 RADIOFREQUENCY 37
  • 6.3 MICROWAVE 37
  • 6.4 IRREVERSIBLE ELECTROPORATION 38
  • 6.5 CRYOABLATION 39
  • 6.6 OTHERS 40

7 GLOBAL TUMOR ABLATION MARKET, BY TREATMENT 41

  • 7.1 OVERVIEW 41
  • 7.2 SURGICAL ABLATION 42
  • 7.3 PERCUTANEOUS ABLATION 42
  • 7.4 LAPAROSCOPIC ABLATION 43

8 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION 44

  • 8.1 OVERVIEW 44
  • 8.2 LUNG CANCER 45
  • 8.3 KIDNEY CANCER 45
  • 8.4 LIVER CANCER 46
  • 8.5 OTHERS 47

9 GLOBAL TUMOR ABLATION MARKET, BY END USER 48

  • 9.1 OVERVIEW 48
  • 9.2 HOSPITAL AND CLINICS 49
  • 9.3 SPECIALITY CENTERS 50
  • 9.4 OTHERS 50

10 GLOBAL TUMOR ABLATION MARKET, BY REGION 51

  • 10.1 OVERVIEW 51
  • 10.2 NORTH AMERICA 52
    • 10.2.1 US 55
    • 10.2.2 CANADA 56
  • 10.3 EUROPE 58
    • 10.3.1 GERMANY 61
    • 10.3.2 FRANCE 62
    • 10.3.3 UK 63
    • 10.3.4 ITALY 65
    • 10.3.5 SPAIN 66
    • 10.3.6 REST OF EUROPE 67
  • 10.4 ASIA PACIFIC 69
    • 10.4.1 CHINA 71
    • 10.4.2 INDIA 72
    • 10.4.3 JAPAN 74
    • 10.4.4 SOUTH KOREA 75
    • 10.4.5 AUSTRALIA 76
    • 10.4.6 REST OF ASIA PACIFIC 78
  • 10.5 REST OF THE WORLD 80
    • 10.5.1 MIDDLE EAST 82
    • 10.5.2 AFRICA 84
    • 10.5.3 LATIN AMERICA 85

11 COMPETITIVE LANDSCAPE 87

  • 11.1 OVERVIEW 87
  • 11.2 COMPETITIVE BENCHMARKING 88
  • 11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL TUMOR ABLATION MARKET 89
  • 11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL TUMOR ABLATION MARKET 90
  • 11.5 KEY DEVELOPMENT ANALYSIS 90
  • 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 91
    • 11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 91
    • 11.6.2 MERGER &ACQUISITION 91
  • 11.7 FINANCIAL MATRIX 92
    • 11.7.1 SALES (USD MILLION), 2020 92
    • 11.7.2 R&D EXPENDITURE (USD MILLION), 2020 92

12 DRG COST OF CURATIVE TREATMENT 93

  • 12.1 DIAGNOSIS-RELATED GROUP (DRG) 93
  • 12.2 BIOPSY PROCEDURE REIMBURSEMENT 93
  • 12.3 ABLATION PROCEDURE REIMBURSMENT 93
    • 12.3.1 LIVER ABLATION PROCEDURE REIMBURSMENT 94
    • 12.3.2 KIDNEY ABLATION PROCEDURE REIMBURSMENT 94
    • 12.3.3 LUNG ABLATION PROCEDURE REIMBURSMENT 95
  • 12.4 IMAGING PROCEDURE REIMBURSMENT 95
  • 12.5 TOTAL CURATIVE TREATMENT COSTS 96

13 COMPANY PROFILES 97

  • 13.1 SONACARE MEDICAL 97
    • 13.1.1 COMPANY OVERVIEW 97
    • 13.1.2 FINANCIAL OVERVIEW 97
    • 13.1.3 PRODUCTS/SERVICES OFFERED 97
    • 13.1.4 KEY DEVELOPMENTS 97
    • 13.1.5 SWOT ANALYSIS 98
    • 13.1.6 KEY STRATEGIES 98
  • 13.2 MEDTRONIC PLC 99
    • 13.2.1 COMPANY OVERVIEW 99
    • 13.2.2 FINANCIAL OVERVIEW 99
    • 13.2.3 PRODUCTS/SERVICES OFFERED 100
    • 13.2.4 KEY DEVELOPMENTS 100
    • 13.2.5 SWOT ANALYSIS 100
    • 13.2.6 KEY STRATEGIES 101
  • 13.3 EDAP TMS 102
    • 13.3.1 COMPANY OVERVIEW 102
    • 13.3.2 FINANCIAL OVERVIEW 102
    • 13.3.3 PRODUCTS/SERVICES OFFERED 103
    • 13.3.4 KEY DEVELOPMENTS 103
    • 13.3.5 SWOT ANALYSIS 103
    • 13.3.6 KEY STRATEGIES 103
  • 13.4 ANGIODYNAMICS 104
    • 13.4.1 COMPANY OVERVIEW 104
    • 13.4.2 FINANCIAL OVERVIEW 104
    • 13.4.3 PRODUCTS/SERVICES OFFERED 105
    • 13.4.4 KEY DEVELOPMENTS 105
    • 13.4.5 SWOT ANALYSIS 105
    • 13.4.6 KEY STRATEGIES 105
  • 13.5 HEALTHTRONICS, INC. 106
    • 13.5.1 COMPANY OVERVIEW 106
    • 13.5.2 FINANCIAL OVERVIEW 106
    • 13.5.3 PRODUCTS/SERVICES OFFERED 106
    • 13.5.4 KEY DEVELOPMENTS 106
    • 13.5.5 SWOT ANALYSIS 107
    • 13.5.6 KEY STRATEGIES 107
  • 13.6 JOHNSON & JOHNSON 108
    • 13.6.1 COMPANY OVERVIEW 108
    • 13.6.2 FINANCIAL OVERVIEW 108
    • 13.6.3 PRODUCTS/SERVICES OFFERED 109
    • 13.6.4 KEY DEVELOPMENTS 109
    • 13.6.5 SWOT ANALYSIS 109
    • 13.6.6 KEY STRATEGIES 109
  • 13.7 BOSTON SCIENTIFIC CORPORATION 110
    • 13.7.1 COMPANY OVERVIEW 110
    • 13.7.2 FINANCIAL OVERVIEW 110
    • 13.7.3 PRODUCTS/SERVICES OFFERED 111
    • 13.7.4 KEY DEVELOPMENTS 111
    • 13.7.5 SWOT ANALYSIS 111
    • 13.7.6 KEY STRATEGIES 112
  • 13.8 MISONIX, INC. 113
    • 13.8.1 COMPANY OVERVIEW 113
    • 13.8.2 FINANCIAL OVERVIEW 113
    • 13.8.3 PRODUCTS/SERVICES OFFERED 114
    • 13.8.4 KEY DEVELOPMENTS 114
    • 13.8.5 SWOT ANALYSIS 114
    • 13.8.6 KEY STRATEGIES 115
  • 13.9 HISTOSONICS, INC. 116
    • 13.9.1 COMPANY OVERVIEW 116
    • 13.9.2 FINANCIAL OVERVIEW 116
    • 13.9.3 PRODUCTS/SERVICES OFFERED 116
    • 13.9.4 KEY DEVELOPMENTS 116
    • 13.9.5 SWOT ANALYSIS 117
    • 13.9.6 KEY STRATEGIES 117
  • 13.10 BIOTRONIK 118
    • 13.10.1 COMPANY OVERVIEW 118
    • 13.10.2 FINANCIAL OVERVIEW 118
    • 13.10.3 PRODUCTS/SERVICES OFFERED 118
    • 13.10.4 KEY DEVELOPMENTS 118
    • 13.10.5 SWOT ANALYSIS 119
    • 13.10.6 KEY STRATEGIES 119

14 APPENDIX 120

  • 14.1 REFERENCES 120
  • 14.2 RELATED REPORTS 120

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16
  • TABLE 2 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 36
  • TABLE 3 GLOBAL TUMOR ABLATION MARKET, FOR RADIOFREQUENCY, BY REGION, 2018-2030 (USD MILLION) 37
  • TABLE 4 GLOBAL TUMOR ABLATION MARKET, FOR MICROWAVE, BY REGION, 2018-2030 (USD MILLION) 38
  • TABLE 5 GLOBAL TUMOR ABLATION MARKET, FOR IRREVERSIBLE ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION) 38
  • TABLE 6 GLOBAL TUMOR ABLATION MARKET, FOR CRYOABLATION, BY REGION, 2018-2030 (USD MILLION) 39
  • TABLE 7 GLOBAL TUMOR ABLATION MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION) 40
  • TABLE 8 GLOBAL: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 41
  • TABLE 9 GLOBAL: TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2018-2030 (USD MILLION) 42
  • TABLE 10 GLOBAL: TUMOR ABLATION MARKET, FOR PERCUTANEOUS ABLATION, BY REGION, 2018-2030 (USD MILLION) 42
  • TABLE 11 GLOBAL: TUMOR ABLATION MARKET, FOR LAPAROSCOPIC ABLATION, BY REGION, 2018-2030 (USD MILLION) 43
  • TABLE 12 GLOBAL: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 44
  • TABLE 13 GLOBAL: TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2018-2030 (USD MILLION) 45
  • TABLE 14 5-YEAR RELATIVE SURVIVAL RATES FOR KIDNEY CANCER 46
  • TABLE 15 GLOBAL: TUMOR ABLATION MARKET, FOR KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION) 46
  • TABLE 16 GLOBAL: TUMOR ABLATION MARKET, FOR LIVER CANCER, BY REGION, 2018-2030 (USD MILLION) 47
  • TABLE 17 GLOBAL: TUMOR ABLATION MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION) 47
  • TABLE 18 GLOBAL: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 48
  • TABLE 19 GLOBAL: TUMOR ABLATION MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2018-2030 (USD MILLION) 49
  • TABLE 20 GLOBAL: TUMOR ABLATION MARKET, FOR SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION) 50
  • TABLE 21 GLOBAL: TUMOR ABLATION MARKET FOR OTHERS, BY REGION, 2018-2030 (USD MILLION) 50
  • TABLE 22 GLOBAL: TUMOR ABLATION MARKET, BY REGION, 2018-2030 (USD MILLION) 51
  • TABLE 23 ESTIMATED NUMBER OF US CANCER SURVIVORS BY SITE (MALE), 2020 52
  • TABLE 24 ESTIMATED NUMBER OF US CANCER SURVIVORS BY SITE (FEMALE), 2020 53
  • TABLE 25 NORTH AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2018-2030 (USD MILLION) 53
  • TABLE 26 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 54
  • TABLE 27 NORTH AMERICA: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 54
  • TABLE 28 NORTH AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 54
  • TABLE 29 NORTH AMERICA: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 55
  • TABLE 30 US: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 55
  • TABLE 31 US: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 55
  • TABLE 32 US: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 56
  • TABLE 33 US: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 56
  • TABLE 34 CANADA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 56
  • TABLE 35 CANADA: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 57
  • TABLE 36 CANADA: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 57
  • TABLE 37 CANADA: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 57
  • TABLE 38 EUROPE: TUMOR ABLATION MARKET, BY COUNTRY, 2018-2030 (USD MILLION) 59
  • TABLE 39 EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 59
  • TABLE 40 EUROPE: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 60
  • TABLE 41 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 60
  • TABLE 42 EUROPE: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 60
  • TABLE 43 GERMANY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 61
  • TABLE 44 GERMANY: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 61
  • TABLE 45 GERMANY: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 61
  • TABLE 46 GERMANY: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 62
  • TABLE 47 FRANCE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 62
  • TABLE 48 FRANCE: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 62
  • TABLE 49 FRANCE: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 63
  • TABLE 50 FRANCE: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 63
  • TABLE 51 UK: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 63
  • TABLE 52 UK: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 64
  • TABLE 53 UK: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 64
  • TABLE 54 UK: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 64
  • TABLE 55 ITALY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 65
  • TABLE 56 ITALY: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 65
  • TABLE 57 ITALY: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 65
  • TABLE 58 ITALY: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 66
  • TABLE 59 SPAIN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 66
  • TABLE 60 SPAIN: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 66
  • TABLE 61 SPAIN: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 67
  • TABLE 62 SPAIN: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 67
  • TABLE 63 REST OF EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 67
  • TABLE 64 REST OF EUROPE: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 68
  • TABLE 65 REST OF EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 68
  • TABLE 66 REST OF EUROPE: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 68
  • TABLE 67 ASIA PACIFIC: TUMOR ABLATION MARKET, BY COUNTRY, 2018-2030 (USD MILLION) 69
  • TABLE 68 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 70
  • TABLE 69 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 70
  • TABLE 70 ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 70
  • TABLE 71 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 71
  • TABLE 72 CHINA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 71
  • TABLE 73 CHINA: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 71
  • TABLE 74 CHINA: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 72
  • TABLE 75 CHINA: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 72
  • TABLE 76 INDIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 72
  • TABLE 77 INDIA: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 73
  • TABLE 78 INDIA: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 73
  • TABLE 79 INDIA: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 73
  • TABLE 80 JAPAN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 74
  • TABLE 81 JAPAN: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 74
  • TABLE 82 JAPAN: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 74
  • TABLE 83 JAPAN: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 75
  • TABLE 84 SOUTH KOREA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 75
  • TABLE 85 SOUTH KOREA: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 75
  • TABLE 86 SOUTH KOREA: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 76
  • TABLE 87 SOUTH KOREA: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 76
  • TABLE 88 AUSTRALIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 76
  • TABLE 89 AUSTRALIA: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 77
  • TABLE 90 AUSTRALIA: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 77
  • TABLE 91 AUSTRALIA: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 77
  • TABLE 92 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 78
  • TABLE 93 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 78
  • TABLE 94 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 78
  • TABLE 95 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 79
  • TABLE 96 REST OF THE WORLD: TUMOR ABLATION MARKET, BY REGION, 2018-2030 (USD MILLION) 80
  • TABLE 97 REST OF THE WORLD: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 81
  • TABLE 98 REST OF THE WORLD: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 81
  • TABLE 99 REST OF THE WORLD: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 82
  • TABLE 100 REST OF THE WORLD: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 82
  • TABLE 101 MIDDLE EAST: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 82
  • TABLE 102 MIDDLE EAST: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 83
  • TABLE 103 MIDDLE EAST: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 83
  • TABLE 104 MIDDLE EAST: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 83
  • TABLE 105 AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 84
  • TABLE 106 AFRICA: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 84
  • TABLE 107 AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 84
  • TABLE 108 AFRICA: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 85
  • TABLE 109 LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 85
  • TABLE 110 LATIN AMERICA: TUMOR ABLATION MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 85
  • TABLE 111 LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 86
  • TABLE 112 LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2018-2030 (USD MILLION) 86
  • TABLE 113 MAJOR PLAYERS IN THE GLOBAL TUMOR ABLATION MARKET 87
  • TABLE 114 MOST ACTIVE PLAYER IN THE GLOBAL TUMOR ABLATION MARKET 90
  • TABLE 115 PRODUCT LAUNCH/PRODUCT APPROVAL 91
  • TABLE 116 MERGER &ACQUISITION 91
  • TABLE 117 BIOPSY PROCEDURE REIMBURSEMENT (USD), 2019 93
  • TABLE 118 LIVER ABLATION PROCEDURE REIMBURSMENT (USD), 2019 94
  • TABLE 119 KIDNEY ABLATION PROCEDURE REIMBURSMENT (USD), 2019 94
  • TABLE 120 LUNG ABLATION PROCEDURE REIMBURSMENT 95
  • TABLE 121 IMAGING PROCEDURE REIMBURSMENT 95
  • TABLE 122 TOTAL CURATIVE TREATMENT COSTS 96
  • TABLE 123 SONACARE MEDICAL: PRODUCTS/SERVICES OFFERED 97
  • TABLE 124 SONACARE MEDICAL: KEY DEVELOPMENTS 97
  • TABLE 125 MEDTRONIC PLC: PRODUCTS/SERVICES OFFERED 100
  • TABLE 126 EDAP TMS: PRODUCTS/SERVICES OFFERED 103
  • TABLE 127 ANGIODYNAMICS: PRODUCTS/SERVICES OFFERED 105
  • TABLE 128 HEALTHTRONICS, INC.: PRODUCTS/SERVICES OFFERED 106
  • TABLE 129 JOHNSON & JOHNSON: PRODUCTS/SERVICES OFFERED 109
  • TABLE 130 BOSTON SCIENTIFIC CORPORATION: PRODUCTS/SERVICES OFFERED 111
  • TABLE 131 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENTS 111
  • TABLE 132 MISONIX, INC.: PRODUCTS/SERVICES OFFERED 114
  • TABLE 133 MISONIX, INC.: KEY DEVELOPMENTS 114
  • TABLE 134 HISTOSONICS, INC.: PRODUCTS/SERVICES OFFERED 116
  • TABLE 135 BIOTRONIK: PRODUCTS/SERVICES OFFERED 118

LIST OF FIGURES

  • FIGURE 1 GLOBAL TUMOR ABLATION MARKET STRUCTURE 17
  • FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 23
  • FIGURE 3 MARKET DYNAMICS ANALYSIS OF THE GLOBAL TUMOR ABLATION MARKET 26
  • FIGURE 4 DRIVERS: IMPACT ANALYSIS 28
  • FIGURE 5 RESTRAINTS: IMPACT ANALYSIS 29
  • FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL TUMOR ABLATION MARKET 30
  • FIGURE 7 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL TUMOR ABLATION MARKET 32
  • FIGURE 8 GLOBAL TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY, 2020-2030 (USD MILLION) 36
  • FIGURE 9 GLOBAL: TUMOR ABLATION MARKET, BY TREATMENT, 2020 & 2030 (USD MILLION) 41
  • FIGURE 10 GLOBAL: TUMOR ABLATION MARKET, BY APPLICATION, 2020 & 2030 (USD MILLION) 44
  • FIGURE 11 GLOBAL: TUMOR ABLATION MARKET, BY END USER, 2020 & 2030 (USD MILLION) 48
  • FIGURE 12 GLOBAL: TUMOR ABLATION MARKET, BY REGION 2020 & 2030 (USD MILLION) 51
  • FIGURE 13 NORTH AMERICA: TUMOR ABLATION MARKET SHARE, BY COUNTRY 2020 (%) 53
  • FIGURE 14 EUROPE, NUMBER OF NEW CANCER CASES IN 2020 58
  • FIGURE 15 EUROPE: TUMOR ABLATION MARKET SHARE (%), BY COUNTRY, 2020 59
  • FIGURE 16 ASIA PACIFIC: TUMOR ABLATION MARKET SHARE (%), BY REGION, 2020 69
  • FIGURE 17 REST OF THE WORLD, NUMBER OF NEW CANCER CASES IN 2020 80
  • FIGURE 18 REST OF THE WORLD: TUMOR ABLATION MARKET SHARE (%), BY REGION, 2020 81
  • FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS 88
  • FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL TUMOR ABLATION MARKET 89
  • FIGURE 21 GLOBAL TUMOR ABLATION MARKET: COMPETITIVE LANDSCAPE 90
  • FIGURE 22 SALES (USD MILLION), 2020 92
  • FIGURE 23 R&D EXPENDITURE (USD MILLION), 2020 92
  • FIGURE 24 SONACARE MEDICAL: SWOT ANALYSIS 98
  • FIGURE 25 MEDTRONIC PLC: FINANCIAL OVERVIEW SNAPSHOT 99
  • FIGURE 26 MEDTRONIC PLC: SWOT ANALYSIS 100
  • FIGURE 27 EDAP TMS: FINANCIAL OVERVIEW SNAPSHOT 102
  • FIGURE 28 EDAP TMS: SWOT ANALYSIS 103
  • FIGURE 29 ANGIODYNAMICS: FINANCIAL OVERVIEW SNAPSHOT 104
  • FIGURE 30 ANGIODYNAMICS: SWOT ANALYSIS 105
  • FIGURE 31 HEALTHTRONICS, INC.: SWOT ANALYSIS 107
  • FIGURE 32 JOHNSON & JOHNSON: FINANCIAL OVERVIEW SNAPSHOT 108
  • FIGURE 33 JOHNSON & JOHNSON: SWOT ANALYSIS 109
  • FIGURE 34 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 110
  • FIGURE 35 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS 111
  • FIGURE 36 MISONIX, INC.: FINANCIAL OVERVIEW SNAPSHOT 113
  • FIGURE 37 MISONIX, INC.: SWOT ANALYSIS 114
  • FIGURE 38 HISTOSONICS, INC.: SWOT ANALYSIS 117
  • FIGURE 39 BIOTRONIK: SWOT ANALYSIS 119